Show simple item record

dc.contributor.authorDodwell, David J
dc.contributor.authorHowell, Anthony
dc.contributor.authorMorton, A R
dc.contributor.authorDaley-Yates, P T
dc.contributor.authorHoggarth, C R
dc.date.accessioned2010-08-16T13:32:58Z
dc.date.available2010-08-16T13:32:58Z
dc.date.issued1992-06
dc.identifier.citationInfusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia. 1992, 68 (800):434-9 Postgrad Med Jen
dc.identifier.issn0032-5473
dc.identifier.pmid1437922
dc.identifier.doi10.1136/pgmj.68.800.434
dc.identifier.urihttp://hdl.handle.net/10541/109623
dc.description.abstractWe report the results of two consecutive randomized studies in the treatment of malignant hypercalcaemia with intravenous pamidronate. Overall normocalcaemia was achieved in greater than 90% of patients and a single infusion of 60 mg pamidronate given over 2 hours was as effective in restoring normocalcaemia as infusions given over 4, 8 or 24 hours. Similarly duration of normocalcemia after treatment with pamidronate and the control of the symptoms of hypercalcaemia were independent of infusion rate. Study of the pharmacokinetics of pamidronate in the treatment of hypercalcaemia show this drug to have a very high clearance due to calcified tissue retention and renal excretion. The initial half life of the drug in plasma is very short and most of the drug is cleared before distribution equilibrium is achieved. Short infusions of pamidronate are as safe and effective as infusions given over a longer time and are therefore to be preferred because of their greater convenience.
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshDiphosphonates
dc.subject.meshDrug Administration Schedule
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshHypercalcemia
dc.subject.meshInfusions, Intravenous
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasms
dc.subject.meshProspective Studies
dc.titleInfusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalPostgraduate Medical Journalen
html.description.abstractWe report the results of two consecutive randomized studies in the treatment of malignant hypercalcaemia with intravenous pamidronate. Overall normocalcaemia was achieved in greater than 90% of patients and a single infusion of 60 mg pamidronate given over 2 hours was as effective in restoring normocalcaemia as infusions given over 4, 8 or 24 hours. Similarly duration of normocalcemia after treatment with pamidronate and the control of the symptoms of hypercalcaemia were independent of infusion rate. Study of the pharmacokinetics of pamidronate in the treatment of hypercalcaemia show this drug to have a very high clearance due to calcified tissue retention and renal excretion. The initial half life of the drug in plasma is very short and most of the drug is cleared before distribution equilibrium is achieved. Short infusions of pamidronate are as safe and effective as infusions given over a longer time and are therefore to be preferred because of their greater convenience.


This item appears in the following Collection(s)

Show simple item record